Overview

Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Primary objective: To assess response rate. To record the clinical improvement in relation to stage and histopathological grading. Secondary objective: To determine progression free survival. To find out overall survival. To evaluate the safety of the study regimen.
Details
Lead Sponsor:
Sanofi
Treatments:
Carboplatin
Docetaxel